The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result.

The market was less than impressed with the top-line results from Viking Therapeutics ' ( VKTX 1.73% ) phase 2 trial of an oral formulation of its anti-obesity drug VK2735. The disappointment created the sense that the stock lacks any near-term catalysts -- phase 3 results from VK2735 in subcutaneous (injection) form aren't likely until 2027 -- and that the excitement around the stock was primarily centered on the oral formulation.

However, that reaction may prove too hasty, and there's still time to buy into the healthcare stock .

What went wrong with Viking Therapeutics' phase 2 Venture trial?

The phase 2 Venture oral dosing trial demonstrated impressive efficacy. Ho

See Full Page